Phase 1 program supports plan to start clinical trials in H2 2022 for NervGen’s NVG-291 in spinal cord injury, multiple sclerosis and Alzheimer’s disease indications Screening of healthy volunteers has already started for the trial’s multiple ascending dose (MAD) portion In preclinical studies, NVG-291 has been shown to promote repair of nervous system damage   … Continue reading NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial